Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2922470 · 2 trials · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days |
| LY2922470 | EXPERIMENTAL | Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A |
| LY2922470 (Part A) | EXPERIMENTAL | Single ascending dose of LY2922470 \[starting at 1 milligram (mg)\] administered orally to healthy participants in up to 3 of 4 study periods in Part A |
| Placebo (Part B) | PLACEBO_COMPARATOR | Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B |
| LY2922470 (Part B) | EXPERIMENTAL | Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered orally as capsules |
| LY2922470 | DRUG | Administered orally as capsules |
Inclusion Criteria: * Must be a male, or a female who cannot become pregnant, and who has type 2 diabetes * Have a glycated hemoglobin (HbA1c) value of greater than or equal to 6.5% and less than or equal to 11% at screening * Do not have any change to their diabetes treatment (exercise with or wit...
LY2922470 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY2922470 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY.
LY2922470 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. Two Phase 1 trials have been completed.
LY2922470 has been studied in two completed Phase 1 trials: NCT01746017, which enrolled 26 participants with Type 2 Diabetes in Singapore, and NCT01867216, which enrolled 66 participants with Type 2 Diabetes in the United States.
LY2922470 is not FDA approved. It is an investigational drug that has completed Phase 1 clinical trials for Type 2 Diabetes Mellitus, but it remains in clinical development and has not received marketing approval.